PUMA BIOTECHNOLOGY, INC. Research and Development Expense (Excluding Acquired in Process Cost)
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Research and Development Expense (Excluding Acquired in Process Cost) of $18.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $18.89M, a 22.28% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $19.80M, a 42.79% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $16.84M, a 11.02% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $15.91M, a 26.82% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for fiscal 2025 was $62.07M, a 12.98% increase from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for fiscal 2024 was $54.94M, a 9.04% increase from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for fiscal 2023 was $50.38M, a 3.56% decline from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. research and development expense (excluding acquired in process cost) for fiscal 2022 was $52.24M, a 27.31% decline from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.89M 10-Q · filed 2026-08-06 | $38.69M 10-Q · filed 2026-08-06 | $55.53M derived: sum of 3 quarters · filed 2026-08-06 | $71.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $19.80M 10-Q · filed 2026-05-07 | $36.64M derived: sum of 2 quarters · filed 2026-05-07 | $52.55M derived: sum of 3 quarters · filed 2026-05-07 | $68.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.75M derived: sum of 2 quarters · filed 2026-02-26 | $48.20M derived: sum of 3 quarters · filed 2026-08-06 | $62.07M 10-K · filed 2026-02-26 |
| 2025-09-30 | $15.91M 10-Q · filed 2025-11-06 | $31.36M derived: sum of 2 quarters · filed 2026-08-06 | $45.23M 10-Q · filed 2025-11-06 | $60.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.45M 10-Q · filed 2026-08-06 | $29.32M 10-Q · filed 2026-08-06 | $44.48M derived: sum of 3 quarters · filed 2026-08-06 | $57.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $13.86M 10-Q · filed 2026-05-07 | $29.03M derived: sum of 2 quarters · filed 2026-05-07 | $41.58M derived: sum of 3 quarters · filed 2026-05-07 | $55.21M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.72M derived: sum of 2 quarters · filed 2026-02-26 | $41.35M derived: sum of 3 quarters · filed 2026-02-26 | $54.94M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.55M 10-Q · filed 2025-11-06 | $26.18M derived: sum of 2 quarters · filed 2025-11-06 | $39.77M 10-Q · filed 2025-11-06 | $52.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $13.63M 10-Q · filed 2025-08-07 | $27.22M 10-Q · filed 2025-08-07 | $40.09M derived: sum of 3 quarters · filed 2026-02-26 | $51.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $13.59M 10-Q · filed 2025-05-08 | $26.46M derived: sum of 2 quarters · filed 2026-02-26 | $37.91M derived: sum of 3 quarters · filed 2026-02-26 | $51.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $12.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.32M derived: sum of 2 quarters · filed 2026-02-26 | $37.68M derived: sum of 3 quarters · filed 2026-02-26 | $50.38M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.45M 10-Q · filed 2024-11-07 | $24.80M derived: sum of 2 quarters · filed 2024-11-07 | $37.51M 10-Q · filed 2024-11-07 | $51.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $13.36M 10-Q · filed 2024-08-01 | $26.06M 10-Q · filed 2024-08-01 | $39.85M derived: sum of 3 quarters · filed 2025-02-27 | $51.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $12.71M 10-Q · filed 2024-05-02 | $26.49M derived: sum of 2 quarters · filed 2025-02-27 | $37.74M derived: sum of 3 quarters · filed 2025-02-27 | $49.71M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $13.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $25.04M derived: sum of 2 quarters · filed 2025-02-27 | $37.00M derived: sum of 3 quarters · filed 2025-02-27 | $52.24M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.25M 10-Q · filed 2023-11-02 | $23.22M derived: sum of 2 quarters · filed 2023-11-02 | $38.46M 10-Q · filed 2023-11-02 | $52.62M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $11.97M 10-Q · filed 2023-08-03 | $27.20M 10-Q · filed 2023-08-03 | $41.37M derived: sum of 3 quarters · filed 2024-02-29 | $60.21M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $15.24M 10-Q · filed 2023-05-04 | $29.41M derived: sum of 2 quarters · filed 2024-02-29 | $48.24M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $33.00M derived: sum of 2 quarters · filed 2024-02-29 | $71.87M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $18.84M 10-Q · filed 2022-11-03 | $57.70M 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $97.65M 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |